ARVN · Arvinas, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ARVN
this stock
Arvinas, Inc.
|
$615.61M | -20.8% | -0.3% | — | 6.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$141.42B | +20.5% | +46.2% | 32.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.84B | +7.2% | +20.8% | 20.9 | 2.3% |
|
ARGX
Argenx SE
|
$64.44B | +22.9% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.96B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ARVN | +2.3% | +7.3% | -23.5% | +2.1% | -20.8% |
| SPY | +0.1% | -0.4% | +15.1% | +0.4% | +12.9% |
| vs SPY | +2.2% | +7.7% | -38.7% | +1.7% | -33.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.